Interestingly, 50% of ALK+ ALCL cases analyzed by tissue microarrays are positive for SHP-1, a negative regulator of the NPM-ALK signaling pathway, which plays an important role in the oncogenesis and has become a therapeutic target in this lymphoma [58]. Here, ALK is linked to lymphoma.